• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Vaccination, infection, and hybrid immunity: determinants of SARS-CoV-2 IgG antibody levels and protection in Quzhou, China

tetano

Editor, Senior Moderator
Front Immunol


. 2025 Jul 28:16:1576016.
doi: 10.3389/fimmu.2025.1576016. eCollection 2025. Vaccination, infection, and hybrid immunity: determinants of SARS-CoV-2 IgG antibody levels and protection in Quzhou, China

Zhiying Yin[SUP] #[/SUP][SUP] 1 [/SUP], Mengcheng Yin[SUP] #[/SUP][SUP] 2 [/SUP], Fei Zhao[SUP] #[/SUP][SUP] 3 [/SUP], Canya Fu[SUP] 3 [/SUP], Wenjie Xu[SUP] 1 [/SUP], Quanjun Fang[SUP] 1 [/SUP], Xiaoying Gong[SUP] 1 [/SUP], Guoping Cao[SUP] 1 [/SUP], Canjie Zheng[SUP] 1 [/SUP]



Affiliations
Abstract

Objectives: To investigate the factors influencing SARS-CoV-2 IgG antibody levels and protection in a population that has experienced both vaccination and COVID-19 infections, predominantly caused by the Omicron BA.5.2 and BF.7 variants.
Methods: Anti-SARS-CoV-2 IgG antibody levels were measured using chemiluminescent microparticle immunoassay (CMIA). Multivariate regression analyses assessed factors influencing antibody levels, and decision tree models predicted variable priorities.
Results: Among the 3494 participants, the median (IQR) anti-SARS-CoV-2 IgG level was 396.53 (280.51-471.03) AU/mL, with a seropositive rate of 97.28%. Multivariate analysis revealed that vaccination status, infection status, residence county, occupation, and vaccination interval were significantly associated with antibody concentration. The decision tree model indicated that vaccination had a greater effect on antibody concentration than infection, while infection had a stronger impact on seropositivity. The Breakthrough Infection group had the highest antibody concentration compared with other groups.
Conclusions: Vaccination and infection were identified as the primary determinants of SARS-CoV-2 IgG antibody levels, with hybrid immunity significantly enhancing antibody responses. New evaluation methods or revised detection thresholds were needed to better assess population immunity.

Keywords: COVID-19; SARS-CoV-2; hybrid immunity; infection; vaccination.

 
Back
Top Bottom